Edgewise grows R&D expenses, losses in fourth quarter

BOULDER — Clinical-stage, pre-revenue pharmaceutical company Edgewise Therapeutics Inc. (Nasdaq: EWTX) posted higher year-over-year losses in the fourth quarter of 2022, driven mostly by additional spending on research and development. 

The company, which markets itself as a developer of “orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders,” posted a net loss of $19.4 million, or 31 cents per share, in the most recent quarter, up from $12.7 million, or 26 cents per share.

Research and development made up $16.6 million of the company’s expenses in the fourth quarter of 2022, an increase over the $9.1 million spent…